sábado, 20 de mayo de 2017

New CDC Report: Spread of resistant fungus, C. auris

New MMWR Notes from the Field:
Ongoing Transmission of Candida auris in Health Care Facilities

A strain of C. auris cultured in a petri dish
 A strain of C. auris cultured
in a petri dish at CDC.
CDC has just released an MMWR update on Candida auris (C. auris) cases identified in U.S. health care facilities through May 2017. C. auris is an emerging fungal infection that presents a serious global health threat for these reasons:
  • it causes serious infections,
  • it is often drug resistant, and
  • it spreads in healthcare settings.
In June 2016, CDC released the first clinical alert about C. auris. Soon after, CDC began reporting on the first U.S. cases. Although C. auris is still rare in the United States, we are seeing an increasing number of cases. The MMWR provides information on the 77 C. auris cases reported to CDC through May 12, 2017.
CDC’s C. auris website provides monthly updates on reported C. auris cases.

What You Can Do
CDC’s website offers question and answer pages for patients and family members and for healthcare workers, and interim recommendations for healthcare facilities and laboratories

What CDC is Doing
CDC provides technical assistance to state health departments when cases are identified and continues to work with partners to contain the spread of C. auris.

Using resources provided by Congress in fiscal year 2016, CDC is making transformative improvements to the nation’s ability to further identify and respond to new and known drug resistance threats, including C. auris:
  • CDC is enhancing national infrastructure in 50 states, five major cities/territories, and seven regions to ensure rapid identification and containment of resistant pathogens and mechanism threats, including C. auris, across all healthcare settings.
  • Regional labs in the CDC AR Lab Network will test for and support response to new forms of Candida resistance in the United States.
  • CDC is enhancing tracking of Candida to better understand the yeast through the Emerging Infections Program.
  • CDC has made C. auris samples available through the CDC AR Isolate Bank to further assist diagnostic labs to calibrate, or standardize, their diagnostic tests so they can accurately identify and characterize this emerging threat. These samples can also assist industry in their work toward innovation for preventing resistant infections like C. auris.
Learn more about how CDC’s Antibiotic Resistance Solutions Initiative is transforming the nation’s capacity to further detect, contain, and prevent drug resistant threats like C. auris.
Learn More

No hay comentarios:

Publicar un comentario